Anidulafungin in the treatment of invasive fungal infections

• Published in: Therapeutics and clinical risk management Vol. 4; no. 1; pp. 71 - 78
• Main Authors: Sabol, Kathryn, Gumbo, Tawanda
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.02.2008; Dove Press; Dove Medical Press
• Subjects: anidulafungin; Antifungal agents; Aspergillus; Candida; candidiasis; efficacy; Evidence-based medicine; pharmacokinetics-pharmacodynamics; Review; anidulafungin; candidiasis; pharmacokinetics-pharmacodynamics; efficacy
• ISSN: 1176-6336; 1178-203X; 1178-203X
• DOI: 10.2147/TCRM.S882

More antifungal agents have reached clinical use in the past two decades than at any other time. The echinocandins have been a welcome addition to this group, with the latest being anidulafungin. There are several lines of evidence to support anidulafungin's role as primary therapy for the treatment of invasive candidiasis in non-neutropenic patients, and as alternative therapy to fluconazole in patients with esophageal candidiasis with azole intolerance or triazole-resistant Candida. Pharmacokinetic-pharmacodynamic studies in animals have demonstrated superior efficacy, defined as maximal microbial kill, when compared to fluconazole, regardless of the fluconazole susceptibility of the Candida species. These studies, as well as dose-effect studies in patients, also support the currently recommended dose of anidulafungin. A well designed randomized controlled trial has demonstrated anidulafungin's efficacy in patients with invasive candidiasis. In this paper, we argue that anidulafungin may be preferable to fluconazole for the treatment of candidemia. However, as of yet, the difference between anidulafungin and the other two licensed echinocandins as first-line therapy for invasive candidiasis is unclear. On the other hand, there is insufficient evidence as of yet to support first-line use of anidulafungin in patients with neutropenia or aspergillosis.